Syngene International Analyst Review May 2026

This Syngene International analyst review for May 2026 covers the key data investors need for SYNGENE at its current price of Rs 930. Syngene International (NSE: SYNGENE) is one of India’s premier contract research and manufacturing services companies with a market capitalisation of approximately Rs 37,000 crore, a subsidiary of Biocon. The analyst consensus target of Rs 1,100 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether SYNGENE achieves that target through FY27.

Click Here – Get Free Investment Predictions

Syngene International Company Snapshot May 2026

Syngene provides integrated drug discovery (biology, chemistry) and development services to global pharma and biotech innovators including BMS, Baxter, and Abbott. Its Dedicated Centre model with multi-year service contracts provides revenue visibility. The table below summarises the key data referenced in this Syngene International analyst review.

Parameter	Value
NSE Ticker	SYNGENE
Sector	Pharma CRAMS – Research Services
CMP (May 2026)	Rs 930
52 Week High	Rs 1,100
52 Week Low	Rs 735
Market Cap	Rs 37,000 Crore
Trailing P/E	38.00x
Analyst Consensus Target	Rs 1,100
Bull Case Target	Rs 1,350
Bear Case Target	Rs 720

Analyst Insight in This Syngene International Analyst Review

Senior Research Analyst Ankit Jaiswal flags Syngene International as a stock to watch in May 2026. At Rs 930, Ankit Jaiswal notes that the key levels for SYNGENE include support in the Rs 750 to Rs 884 band and resistance near Rs 986. He suggests watching Syngene International for a potential move toward the consensus target of Rs 1,100, contingent on Pharma CRAMS – Research Services sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Syngene International analyst review and does not constitute a trade recommendation.

Technical Analysis in This Syngene International Analyst Review

At Rs 930, SYNGENE is trading within its 52-week band of Rs 735 to Rs 1,100. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 750 to Rs 884 band while resistance is seen in the Rs 986 to Rs 1,015 zone. A sustained move above Rs 986 could open the path toward the analyst consensus of Rs 1,100.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 750 to Rs 884 – investors tracking this Syngene International analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 986 to Rs 1,015 – a sustained close above Rs 986 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 1,100 represents the base-case upside for this Syngene International analyst review.

Business Segment Analysis

Drug Discovery Research Services (Integrated Biology and Chemistry)

This is the primary revenue and margin driver for Syngene International, directly supporting the earnings trajectory toward the consensus target of Rs 1,100.

Commercial Manufacturing and Clinical Supplies

This segment adds scale and diversification to Syngene International’s business model and is a meaningful EPS contributor through FY27 and FY28.

Dedicated Research Centres for Global Pharma Clients

This represents the medium-term growth frontier for Syngene International and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Syngene International Analyst Review

At Rs 930, Syngene International trades at a trailing P/E of 38.00x. This Syngene International analyst review presents three scenarios: a bull case of Rs 1,350 on strong earnings delivery, a base case of Rs 1,100 at consensus, and a bear case of Rs 720 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,350	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 1,100	Moderate growth, analyst consensus estimate
Bear Case	Rs 720	Earnings miss or macro headwinds

Trade Outlook for Syngene International

Based on the technical and fundamental analysis in this Syngene International analyst review, investors might watch SYNGENE near the support zone of Rs 750 to Rs 884 for potential opportunities. A flag above Rs 986 could suggest improving momentum toward Rs 1,100. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Syngene International in FY27

A well-rounded Syngene International analyst review must assess downside risks. Key risks for Syngene International include a macro slowdown affecting Pharma CRAMS – Research Services sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in SYNGENE.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Syngene International Analyst Review Verdict for 2026

This Syngene International analyst review concludes that at Rs 930, SYNGENE offers a defined risk-reward with a consensus target of Rs 1,100. The 52-week range of Rs 735 to Rs 1,100 provides context on the current entry point. Use this Syngene International analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on SYNGENE.

Frequently Asked Questions: Syngene International Analyst Review 2026

What is the analyst target for Syngene International in 2026?

The analyst consensus target is Rs 1,100, with a bull case of Rs 1,350 and a bear case of Rs 720. Monitor Q1 FY27 earnings for confirmation.

Is Syngene International a good investment at Rs 930?

At Rs 930 with a P/E of 38.00x and a consensus target of Rs 1,100, this Syngene International analyst review is constructive for medium to long-term investors in the Pharma CRAMS – Research Services sector. Always consult a SEBI-registered advisor before investing.

What is Syngene International’s 52-week high and low?

The 52-week high is Rs 1,100 and the 52-week low is Rs 735. At Rs 930, SYNGENE is positioned within this range as noted in this Syngene International analyst review.

What are the key risks for Syngene International?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharma CRAMS – Research Services sector.

Where can I get live data and analyst targets for Syngene International?

Track Syngene International’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.